Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jerald Radich

Showing results (21-30 of 100) with videos related to

Pageof 10
Sort By:
American Journal of Hematology|April 10, 2016
Monitoring disease burden in chronic myeloid leukemia: Past, present, and futureDaniel Egan, Jerald Radich
Journal of the National Comprehensive Cancer Network : JNCCN|March 15, 2013
Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemiaMerav Bar, Jerald Radich
Current Hematologic Malignancy Reports|April 12, 2017
Predicting Chemotherapy Resistance in AMLCecilia C S Yeung, Jerald Radich
Blood|September 20, 2019
New approaches to molecular monitoring in CML (and other diseases)Jerald Radich, Cecilia Yeung, David Wu
Future Oncology (London, England)|February 6, 2026
A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®)Michael Mauro, Jerald Radich, Dan Douer
Clinical Advances in Hematology & Oncology : H&O|November 29, 2012
Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemiaJorge Cortes, Jerald Radich, Michael J Mauro
Journal of the National Comprehensive Cancer Network : JNCCN|October 3, 2009
Update: chronic myelogenous leukemia clinical practice guidelinesSusan M O'Brien, Hagop Kantarjian, Jerald Radich
Hematology. American Society of Hematology. Education Program|December 7, 2019
Meeting the needs of CML patients in resource-poor countriesHemant Malhotra, Jerald Radich, Pat Garcia-Gonzalez
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2016
What Happens When Imatinib Goes Generic?Jean McDougall, Scott D Ramsey, Jerald Radich
Current Hematologic Malignancy Reports|March 7, 2016
New Methodologies in the Molecular Monitoring of CMLCecilia C S Yeung, Daniel Egan, Jerald Radich
Pageof 10

Showing results (21-30 of 100) with videos related to

Sort By:
Pageof 10
American Journal of Hematology|April 10, 2016
Monitoring disease burden in chronic myeloid leukemia: Past, present, and futureDaniel Egan, Jerald Radich
Journal of the National Comprehensive Cancer Network : JNCCN|March 15, 2013
Maintenance therapy with tyrosine kinase inhibitors after transplant in patients with chronic myeloid leukemiaMerav Bar, Jerald Radich
Current Hematologic Malignancy Reports|April 12, 2017
Predicting Chemotherapy Resistance in AMLCecilia C S Yeung, Jerald Radich
Blood|September 20, 2019
New approaches to molecular monitoring in CML (and other diseases)Jerald Radich, Cecilia Yeung, David Wu
Future Oncology (London, England)|February 6, 2026
A plain language summary of how the body processes a lower-dose nilotinib tablet (Danziten™) compared to the existing capsule (Tasigna®)Michael Mauro, Jerald Radich, Dan Douer
Clinical Advances in Hematology & Oncology : H&O|November 29, 2012
Clinical roundtable monograph: Emerging treatment options for TKI-resistant chronic myelogenous leukemiaJorge Cortes, Jerald Radich, Michael J Mauro
Journal of the National Comprehensive Cancer Network : JNCCN|October 3, 2009
Update: chronic myelogenous leukemia clinical practice guidelinesSusan M O'Brien, Hagop Kantarjian, Jerald Radich
Hematology. American Society of Hematology. Education Program|December 7, 2019
Meeting the needs of CML patients in resource-poor countriesHemant Malhotra, Jerald Radich, Pat Garcia-Gonzalez
Journal of the National Comprehensive Cancer Network : JNCCN|February 7, 2016
What Happens When Imatinib Goes Generic?Jean McDougall, Scott D Ramsey, Jerald Radich
Current Hematologic Malignancy Reports|March 7, 2016
New Methodologies in the Molecular Monitoring of CMLCecilia C S Yeung, Daniel Egan, Jerald Radich
Pageof 10